Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Loma Linda University
With
Novo Nordisk A/S
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Self-identify as being of Hispanic/Latino ethnicity
BMI \>30
Age 18-75 years old
Able to provide informed consent before any trial related activities
You may not be if
Current cancer treatment
Diabetes, Type 1 or Type 2
Eating disorders
Medication use targeting the GPL-1 system
In the last 30 days, attempted to lose weight by lifestyle modification alone or with the use of anti-obesity medications resulting in more than 5 pounds of weight loss.
History of bariatric surgery
Use of obesogenic medications (including but not limited to steroids, haloperidol, clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and lithium) which cannot be substituted or stopped.
Pregnant or planning to become pregnant in the next 8 months
Genetic disorders and/or physical or mental handicaps that would limit participation in the study and/or the intensive lifestyle intervention.
Any contraindication to semaglutide 2.4 mg including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2, hypersensitivity to semaglutide 2.4 mg or any product components.
Any known or suspected allergy to semaglutide 2.4 mg or related products
Previous participation in this trial, either initial screening or group randomization
